Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor Felix

Showing results (31-40 of 147) with videos related to

Pageof 15
Sort By:
Neurogenetics|May 15, 2012
Dissecting the clinical phenotype associated with mosaic type-2 NF1 microdeletionsHildegard Kehrer-Sawatzki, Julia Vogt, Tanja Mußotter, et al.
Human Genetics|November 28, 2018
Ultra-deep amplicon sequencing indicates absence of low-grade mosaicism with normal cells in patients with type-1 NF1 deletionsAnna Summerer, Eleonora Schäfer, Victor-Felix Mautner, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|November 8, 2017
Motor dysfunction in NF1: Mediated by attention deficit or inherent to the disorder?Karin Haas-Lude, Magdalena Heimgärtner, Sarah Winter, et al.
Human Mutation|September 2, 2017
Consideration of the haplotype diversity at nonallelic homologous recombination hotspots improves the precision of rearrangement breakpoint identificationMorten Hillmer, Anna Summerer, Victor-Felix Mautner, et al.
Journal of Neuro-Oncology|October 30, 2013
Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1Rosa Nguyen, Kimberly Jett, Gordon J Harris, et al.
International Journal of Pediatrics|January 10, 2020
Attention Deficit Predicts Intellectual Functioning in Children with Neurofibromatosis Type 1Magdalena Heimgärtner, Sofia Granström, Karin Haas-Lude, et al.
Anticancer Research|February 4, 2019
Manifestations and Treatment of Adult-onset Symptomatic Optic Pathway Glioma in Neurofibromatosis Type 1Juliane Mehlan, Frank Schüttauf, Johannes M Salamon, et al.
Experimental Neurology|June 8, 2017
Neuropathies in the setting of Neurofibromatosis tumor syndromes: Complexities and opportunitiesAlexander Schulz, Peter Grafe, Christian Hagel, et al.
The Journal of Investigative Dermatology|September 19, 2008
Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromasKatharina Steinmann, Lan Kluwe, Reinhard E Friedrich, et al.
Plos One|November 14, 2017
MEK inhibitors enhance therapeutic response towards ATRA in NF1 associated malignant peripheral nerve sheath tumors (MPNST) in-vitroSusan Fischer-Huchzermeyer, Anna Dombrowski, Gordon Wilke, et al.
Pageof 15

Showing results (31-40 of 147) with videos related to

Sort By:
Pageof 15
Neurogenetics|May 15, 2012
Dissecting the clinical phenotype associated with mosaic type-2 NF1 microdeletionsHildegard Kehrer-Sawatzki, Julia Vogt, Tanja Mußotter, et al.
Human Genetics|November 28, 2018
Ultra-deep amplicon sequencing indicates absence of low-grade mosaicism with normal cells in patients with type-1 NF1 deletionsAnna Summerer, Eleonora Schäfer, Victor-Felix Mautner, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|November 8, 2017
Motor dysfunction in NF1: Mediated by attention deficit or inherent to the disorder?Karin Haas-Lude, Magdalena Heimgärtner, Sarah Winter, et al.
Human Mutation|September 2, 2017
Consideration of the haplotype diversity at nonallelic homologous recombination hotspots improves the precision of rearrangement breakpoint identificationMorten Hillmer, Anna Summerer, Victor-Felix Mautner, et al.
Journal of Neuro-Oncology|October 30, 2013
Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1Rosa Nguyen, Kimberly Jett, Gordon J Harris, et al.
International Journal of Pediatrics|January 10, 2020
Attention Deficit Predicts Intellectual Functioning in Children with Neurofibromatosis Type 1Magdalena Heimgärtner, Sofia Granström, Karin Haas-Lude, et al.
Anticancer Research|February 4, 2019
Manifestations and Treatment of Adult-onset Symptomatic Optic Pathway Glioma in Neurofibromatosis Type 1Juliane Mehlan, Frank Schüttauf, Johannes M Salamon, et al.
Experimental Neurology|June 8, 2017
Neuropathies in the setting of Neurofibromatosis tumor syndromes: Complexities and opportunitiesAlexander Schulz, Peter Grafe, Christian Hagel, et al.
The Journal of Investigative Dermatology|September 19, 2008
Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromasKatharina Steinmann, Lan Kluwe, Reinhard E Friedrich, et al.
Plos One|November 14, 2017
MEK inhibitors enhance therapeutic response towards ATRA in NF1 associated malignant peripheral nerve sheath tumors (MPNST) in-vitroSusan Fischer-Huchzermeyer, Anna Dombrowski, Gordon Wilke, et al.
Pageof 15